In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations

Executive Summary

Bifurcated lesions remain one of the most challenging unmet clinical needs facing interventional cardiologists, even with current drug-eluting stents. Here's how one small company is challenging bigger players in this promising market by developing polymer-free DES designed specifically for these difficult bifurcated lesions.

Related Content

Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Tryton Medical: Going Against the Flow in Bifurcated Stents
Stentys' Shifting Focus: Moving Beyond Bifurcations, Stenting for AMI
The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs
VCs Keep Capital Flowing To Stent Start-Ups
Invatec: From Garage to Global Cardiology Brand
Bifurcation Stenting: The Next Generation
Cappella Inc.
Stents Branch Out and Return to Their Start-Up Roots
Invatec: Italy's Home-Grown Device Model





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts